Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

To join this study, you would need to have advanced cancer that has spread or can't be removed with surgery. Your cancer would also need to have a specific marker called Nectin-4. You should have already tried other standard treatments for your cancer, but there are no more established treatments currently available that are known to work for your specific type at this stage. You would also need to be generally well enough to take part and have your main body organs working properly.

There are also some reasons why people might not be able to join. For example, if you have cancer that has spread to your brain, serious ongoing infections, or certain heart conditions, you might not be eligible. If you've had major surgery recently, are on certain other medications like strong blood thinners or some steroids, or have a lung condition called interstitial lung disease, you also might not be able to take part.

If you decide to take part in this study, you will receive the new medicine, IPH4502. Because it's a first-time-in-human study, you'll have regular hospital visits to check your health, manage any side effects, and see how the medicine is affecting your cancer. These visits will involve blood tests, scans, and other checks. You might also be asked to provide a recent tissue sample from your cancer or have a new small procedure to collect one.

The study will start with a gradual increase in the dose of IPH4502 for different groups of patients to find the safest and most effective amount. The total duration of your participation would depend on how your body reacts to the medicine and how your cancer responds, but you would be regularly monitored throughout. You would also have follow-up appointments after stopping the treatment.